Search

Eli Lilly and Co.

Nyitva

SzektorEgészségügy

1,434.89 -0.6

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

1440.09

Maximum

1474.75

Fő mutatók

By Trading Economics

Bevétel

-644M

6.5B

Értékesítés

1.4B

24B

P/E

Szektor átlag

43.945

68.089

Egy részvényre jutó nyereség

7.48

Osztalékhozam

0.49

Profit margin

26.442

Munkavállalók

50,000

EBITDA

-3.7B

9.3B

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+5.31% upside

Osztalékok

By Acuity

Osztalékhozam

Szektor átlag

0.49%

1.98%

Következő eredményjelentés

2027. febr. 3.

Következő osztalékfizetési dátum

2026. dec. 10.

Következő korábbi osztalék dátum

2027. febr. 12.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

118B

1.3T

Előző nyitás

1435.49

Előző zárás

1434.89

Eli Lilly and Co. Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. nov. 14. 01:01 UTC

Eli Lilly and Company shares are declining in after-market trading, having pulled back from a brief peak shortly after the market closed.

2026. nov. 13. 23:01 UTC

Eli Lilly and Company shares are modestly lower in after-market trading, reflecting a broadly declining market amid rising inflation concerns and Treasury yields.

2026. nov. 12. 23:02 UTC

Eli Lilly and Company shares are trading lower in after-market hours, reflecting a slight decline since Thursday's close, despite strong one-month gains.

2026. nov. 11. 23:03 UTC

News
Event

Eli Lilly reports positive results from the TOGETHER-PsA trial, showing Taltz and Zepbound's efficacy in treating psoriatic arthritis with weight-related comorbidities.

2026. nov. 9. 21:04 UTC

Social Media
Event
News

Eli Lilly reports positive Phase 3 trial results for Foundayo, showing significant reductions in obstructive sleep apnea severity among adults with obesity or overweight.

2026. nov. 7. 00:02 UTC

Event

Eli Lilly and Company announces agreement with Hims & Hers Health to expand access to medications Zepbound and Foundayo.

2026. nov. 6. 23:02 UTC

Event

Eli Lilly announces agreement with Hims & Hers to enhance access to medications Zepbound and Foundayo, with shares trading roughly flat in after-market hours.

2026. nov. 5. 23:03 UTC

Eli Lilly shares are trading modestly lower in after-market hours, reflecting a broader market decline amid significant drops in major semiconductor stocks.

2026. nov. 4. 23:02 UTC

Eli Lilly and Company shares gained modestly in after-market trading, remaining near the upper end of their one-month range following fluctuating returns.

2026. nov. 3. 23:01 UTC

Eli Lilly and Company shares are trading modestly lower in after-market hours, retreating from a brief peak earlier in the session.

2026. nov. 2. 23:06 UTC

Eli Lilly and Company is experiencing a modest increase in after-market trading, gaining slightly since Monday's close and positioned above its 20-day moving average.

2026. okt. 30. 23:01 UTC

Social Media
News

JP Morgan maintains Overweight rating on Eli Lilly and raises price target to $165, with shares trading modestly higher in after-market hours.

2026. okt. 29. 23:03 UTC

Eli Lilly and Company shares advanced during after-market hours, reflecting a broader upward trend in the Pharmaceuticals sub-sector.

2026. okt. 28. 23:02 UTC

Event
Social Media

Eli Lilly announces positive topline results from its Phase 3 trial comparing retatrutide to Ozempic in adults with type 2 diabetes.

2026. okt. 27. 20:07 UTC

Social Media
News

Eli Lilly announces a fourth-quarter 2026 dividend of $1.73 per share and reports strong Q2 results with net income of $7.09 billion.

2026. okt. 23. 20:02 UTC

Social Media
News
Correlated Moves

Eli Lilly and Co shares are declining, continuing a downward trend since Thursday's close, while the broader Pharmaceuticals sector is also lower.

2026. okt. 22. 20:07 UTC

Correlated Moves
Social Media
News

Eli Lilly breaks ground on a $5 billion manufacturing facility in Virginia, expected to create 650 permanent jobs and support U.S. manufacturing initiatives.

2026. okt. 21. 20:07 UTC

News
Correlated Moves

Leerink Partners raised Eli Lilly's price target to $1.32k, while RBC Capital set a target of $1.5k, but shares are declining in today's session.

2026. okt. 20. 23:02 UTC

News

Eli Lilly named RBC Capital's preferred pharmaceutical stock with a $1.5K price target, despite shares declining modestly in after-market hours.

2026. okt. 19. 23:06 UTC

Event

Eli Lilly announces positive Phase 3 SHINE-2 study results for Omvoh in pediatric ulcerative colitis, with 81% of participants achieving clinical response at Week 12.

2026. okt. 17. 00:01 UTC

Eli Lilly and Co shares are lower in after-market hours, reflecting broader market declines amid stronger-than-expected inflation metrics and significant inflows in U.S. TIC Flows.

2026. okt. 16. 23:06 UTC

Eli Lilly and Co shares are trading slightly lower in after-market hours, reflecting routine fluctuations amid a stable broader market context.

2026. okt. 15. 23:11 UTC

Social Media
Event

Eli Lilly announces new data showing treatment goals achieved for ulcerative colitis and Crohn's disease patients with Omvoh after one year.

2026. okt. 14. 23:42 UTC

Social Media

Eli Lilly and Co's shares are trading lower in after-market hours, reflecting a broader market decline amid rising Treasury yields and inflation concerns.

2026. okt. 13. 20:02 UTC

News
Correlated Moves
Social Media

Eli Lilly announces a clinical trial collaboration with Prelude Therapeutics for a Phase 1 trial involving abemaciclib and imlunestrant, contributing to bearish sentiment.

2026. okt. 12. 20:07 UTC

News
Event
Social Media

Eli Lilly gains support as RBC Capital reiterates Outperform rating with a $1.5K price target, following new data from the TOGETHER-PsO Phase 3b trial.

2026. okt. 9. 20:07 UTC

Social Media
Event
News
Correlated Moves

Eli Lilly presents new data from its Phase 3b TOGETHER-PsO trial, showing significant biomarker changes with the combination of Taltz and Zepbound for psoriasis treatment.

2026. okt. 8. 23:05 UTC

Eli Lilly and Co shares are trading lower in after-market hours, reflecting a decline since Thursday's close and fluctuating near the lower end of its recent range.

2026. okt. 7. 23:06 UTC

Eli Lilly and Co is trading slightly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month trading range.

2026. okt. 6. 20:07 UTC

Social Media
News
Event

Eli Lilly contributed to a $120 million Series B funding round for General Medicine, raising total funding to $152 million, amid positive market sentiment.

Társak összehasonlítása

Árváltozás

Eli Lilly and Co. Előrejelzés

Célár

By TipRanks

5.31% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 1,520.136 USD  5.31%

Magas 1,700 USD

Alacsony 940 USD

24 Wall Street elemző 12 hónapos célárain alapulva a(z)Eli Lilly and Co. termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

24 ratings

22

Vétel

1

Tartás

1

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
help-icon Live chat